Sorry guys, Spelled the drug wrong: Here some info:
FDA-Approved Drugs: Vorinostat (Zolinza, suberoylanilide hydroxamic acid [SAHA])
Investigational Drugs: CRA-024781 (Celera Genomics), depsipeptide (Romidepsin)
Mechanism of Action
DNA coils around histones, which are proteins that help push the DNA strands into tightly coiled chromatin in the nucleus of the cell. Histones play an important role in turning genes on and off. When the chromatin is loose and uncoiled, the gene is turned on and DNA transcription can occur. If there is too much deacetylation of the histones (caused by an overexpression of histone deacetylase), such as may occur in cancer, the chromatin is tightly coiled and closed, so that the gene is turned off (cannot be transcribed). Deacetylation is the removal of acetyl groups from proteins or transcription factors. For example, if the gene that is silenced is a tumor suppressor gene, then without the "brakes" on cell division, cancer cells may proliferate. Another gene that may be silenced is a cyclin kinase inhibitor, which regulates the cell cycle. Again, the tumor would be able to continue to divide and make more tumor cells. Imagine a Slinky toy as a DNA coiled helix. When you move it so that the rings are open, you see that the portion of DNA that codes for the gene is exposed. When the rings are open, the gene can be activated and transcribed. When the Slinky moves down a step, it closes in on itself, and there is no way that the gene can be exposed for transcription. Vorinostat is a histone deacetylase (HDAC) inhibitor, which blocks the deacetylase enzyme and allows the acetyl groups to accumulate on the histones. This uncoils the DNA within the chromatin so that genes are exposed; they become activated and are then transcribed. This causes cancer cells to stop dividing (cell cycle arrest) and to die (apoptosis).
The drug is well absorbed, and if taken with a high-fat meal had a 33% higher extent of absorption and a slightly slower rate of absorption (not clinically significant). The drug is primarily metabolized by glucuronidation and hydrolysis, followed by oxidation into two inactive metabolites. Less than 1% of the drug is recoverable in the urine.
Vorinostat is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease during or after two systemic therapies.
Educate the patient about the correct oral administration of vorinostat: swallow the prescribed capsules (400 mg) whole (do not chew or break), once a day with food. Drink at least eight 8-ounce glasses of liquid a day.